Pliant Therapeutics Inc (PLRX)
13.45
-0.32
(-2.32%)
USD |
NASDAQ |
Nov 14, 11:05
Pliant Therapeutics PE Ratio
PE Ratio Chart
Historical PE Ratio Data
| Date | Value |
|---|---|
| June 29, 2020 | 114.79 |
| June 26, 2020 | 103.27 |
| June 25, 2020 | 101.18 |
| June 24, 2020 | 99.03 |
| June 23, 2020 | 96.10 |
| June 22, 2020 | 91.15 |
| June 19, 2020 | 91.19 |
| June 18, 2020 | 86.73 |
| June 17, 2020 | 84.61 |
| June 16, 2020 | 81.52 |
| Date | Value |
|---|---|
| June 15, 2020 | 83.63 |
| June 12, 2020 | 74.39 |
| June 11, 2020 | 74.00 |
| June 10, 2020 | 75.79 |
| June 09, 2020 | 71.62 |
| June 08, 2020 | 75.53 |
| June 05, 2020 | 72.44 |
| June 04, 2020 | 76.05 |
| June 03, 2020 | 69.34 |
Price to Earnings Ratio (PE Ratio) Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS Diluted (TTM). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.
PE Ratio Range, Past 5 Years
69.34
Minimum
Jun 03 2020
114.79
Maximum
Jun 29 2020
85.39
Average
83.63
Median
Jun 15 2020
PE Ratio Benchmarks
| Haemonetics Corp | 38.37 |
| Marker Therapeutics Inc | -- |
| Aligos Therapeutics Inc | -- |
| Korro Bio Inc | -- |
| CEL-SCI Corp | -- |
PE Ratio Related Metrics
| PS Ratio | 161.34 |
| Price to Book Value | 2.367 |
| Price | 13.45 |
| Earnings Yield | -24.83% |
| Market Cap | 818.48M |